Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs
By Dominic Chopping
An Indian court allowed Dr. Reddy's Laboratories to manufacture and export generic versions of Novo Nordisk's blockbuster diabetes and weight-loss drugs.
In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk's application to block production of semaglutide--the key ingredient in Ozempic and Wegovy--allowing the Indian drugmaker to make the drug and export it to countries where it doesn't have patent protection.
The decision comes as the patent for semaglutide is due to expire in India early next year.
According to court documents, Dr. Reddy's confirmed that it wouldn't sell the drug in India until the patent expires next March, and the court ordered the company to keep a record of the quantity and value of the products its manufactures and sells.
Dr. Reddy's began producing the drug in April this year, according to the documents.
Patent protections for semaglutide expire in India, Canada, Brazil and China next year, clearing the way for cheaper generic versions to be sold in those markets. In Europe, the U.S. and Japan, patents aren't due to expire until the 2030s.
Novo Nordisk has the option to appeal to the Supreme Court.
Novo Nordisk and Dr. Reddy's didn't respond to requests for comment.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
December 04, 2025 05:42 ET (10:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States